[Emerging therapy in rheumatoid arthritis].
Rheumatoid arthritis (RA) is a chronic disease leading to disability. The inflammatory process resulting from autoimmunization involves mainly small joints of the hands and feet, but also can involve all joints and internal organs. Progress in immunology has caused an increase in understanding the RA pathogenesis, resulting in new methods of treatment. The breakthrough in RA therapy was initiated by TNF- alpha inhibitors, introduced during the last 10 years. TNF- alpha inhibitors were the first medications allowing improvement of disease outcome. However, more than half of patients do not achieve ACR50 improvement criteria, remission is rare, and the treatment is associated with side effects. Therefore, new and better drugs are being sought. In this review, new preparations for RA treatment currently under preclinical and clinical examination are described.
Kańska
Urszula
U
Instytut Immunologii i Terapii Doświadczalnej Polskiej Akademii Nauk im. L. Hirszfelda we Wrocławiu.
Boratyński
Janusz
J
D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000503:physiopathology; D001327:Autoimmune Diseases / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D053264:B-Cell Activating Factor / Q000037:antagonists & inhibitors / Q000627:therapeutic use; D001688:Biological Products / Q000627:therapeutic use; D016207:Cytokines / Q000037:antagonists & inhibitors; D004359:Drug Therapy, Combination; D006801:Humans; D007378:Interleukins / Q000037:antagonists & inhibitors; D007596:Joints / Q000276:immunology / Q000378:metabolism / Q000503:physiopathology*; D047428:Protein Kinase Inhibitors; D018124:Receptors, Tumor Necrosis Factor / Q000378:metabolism; D015398:Signal Transduction; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D020533:Angiogenesis Inhibitors; D000894:Anti-Inflammatory Agents, Non-Steroidal; D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D053264:B-Cell Activating Factor; D001688:Biological Products; D016207:Cytokines; D007378:Interleukins; D047428:Protein Kinase Inhibitors; D018124:Receptors, Tumor Necrosis Factor; C505719:TNFSF13B protein, human; D014409:Tumor Necrosis Factor-alpha